CD4 and metastatic colorectal cancer: Furthermore, highly immune CD4+ T cells that recognize COA- 1, telomerase reverse transcriptase (TERT), and mesothelin-derived peptides have been shown in patients with chemotherapy-naïve metastatic colorectal cancer (mCRC) and CD4+ T cells have been shown to sustain their anti-tumor functions for three months during oxaliplatin treatment.45